Objetivo Cancer heterogeneity has reinforced the need for personalized treatment modalities. Pre-therapeutic diagnostic testing of heterogeneous tumors helps avoid inefficacious treatments, optimizes targeted therapy, and improves quality of life. Within targeted therapy, immunotherapy has led to significant improvements in treatment outcomes and is swiftly being integrated in diagnostic workflows. In this context, routine diagnostic tests currently do not exist, and treatments are further challenged by heterogeneity. Spatially resolved molecular probing of tumors prior to treatment would allow prediction of patient response to immunotherapeutics.We have been developing methods to perform local biochemical reactions at micrometer length scales using nanoliter volumes of biochemicals. These methods are implemented using a scanning probe technology – the microfluidic probe (MFP) – with devices, platforms and assays adapted for application on biological substrates. With this, we are working towards multi-modal molecular profiling of tumors – tissue microprocessing (TMP). Thus far, we have demonstrated TMP for local DNA and mRNA analysis on live cells, for patterning cells and for micro-immunohistochemical tests on tissues. Here, we will leverage TMP concepts to work on the initial steps in pre-commercializing the MFP for diagnostic testing in immunotherapy. Specifically, we aim to(1) develop assays for morphological and molecular analyses of pancreatic tissues using the MFP (2) adapt the assays developed in (1) to be compatible with workflows of state-of-the-art genome and transcriptome analysis for molecular profiling of tumors in diagnostics(3) validate these techniques for patient samples.With this PoC grant, we envision to translate the MFP technology from the lab to the clinic for personalized immunotherapy. Ámbito científico natural sciencesbiological sciencesgeneticsDNAmedical and health sciencesclinical medicineoncologymedical and health sciencesbasic medicineimmunologyimmunotherapynatural sciencesbiological sciencesgeneticsgenomes Programa(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Tema(s) ERC-PoC-2016 - ERC-Proof of Concept-2016 Convocatoria de propuestas ERC-2016-PoC Consulte otros proyectos de esta convocatoria Régimen de financiación ERC-POC - Proof of Concept Grant Institución de acogida IBM RESEARCH GMBH Aportación neta de la UEn € 150 000,00 Dirección SAEUMERSTRASSE 4 8803 Rueschlikon Suiza Ver en el mapa Región Schweiz/Suisse/Svizzera Zürich Zürich Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 150 000,00 Beneficiarios (1) Ordenar alfabéticamente Ordenar por aportación neta de la UE Ampliar todo Contraer todo IBM RESEARCH GMBH Suiza Aportación neta de la UEn € 150 000,00 Dirección SAEUMERSTRASSE 4 8803 Rueschlikon Ver en el mapa Región Schweiz/Suisse/Svizzera Zürich Zürich Tipo de actividad Private for-profit entities (excluding Higher or Secondary Education Establishments) Enlaces Contactar con la organización Opens in new window Sitio web Opens in new window Participación en los programas de I+D de la UE Opens in new window Red de colaboración de HORIZON Opens in new window Coste total € 150 000,00
